LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses
Science Immunology · 17.05.2024 · 9 (95)
DOI: 10.1126/sciimmunol.adi7418 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Immunology, erschienen am 17.05.2024. Verfasst von Hieu Minh Ta und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA. Hauptthemen laut MEDLINE: B7 Antigens, CD8-Positive T-Lymphocytes, Membrane Glycoproteins, Tumor Microenvironment. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Wellcome Trust, NIH HHS.
Abstract (Originalsprache)
Immune checkpoint blockade is a promising approach to activate antitumor immunity and improve the survival of patients with cancer. V-domain immunoglobulin suppressor of T cell activation (VISTA) is an immune checkpoint target; however, the downstream signaling mechanisms are elusive. Here, we identify leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) as a VISTA binding partner, which acts as an inhibitory receptor by engaging VISTA and suppressing T cell receptor signaling pathways. Mice with T cell–specific LRIG1 deletion developed superior antitumor responses because of expansion of tumor-specific cytotoxic T lymphocytes (CTLs) with increased effector function and survival. Sustained tumor control was associated with a reduction of quiescent CTLs (TCF1 + CD62L hi PD-1 low ) and a reciprocal increase in progenitor and memory-like CTLs (TCF1 + PD-1 + ). In patients with melanoma, elevated LRIG1 expression on tumor-infiltrating CD8 + CTLs correlated with resistance to immunotherapies. These results delineate the role of LRIG1 as an inhibitory immune checkpoint receptor and propose a rationale for targeting the VISTA/LRIG1 axis for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
- Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Department of Inflammation and Immunology, Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
- Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
- Case Comprehensive Cancer Center, Cleveland, OH, USA.
ORCID-Profile: Hieu Minh Ta, Dia Roy, Keman Zhang, Tyler Alban, Prerana B Parthasarathy, Sachin Patnaik, Elizabeth Delaney, Cassandra Gilmour, Amin Zakeri, Amit Rupani, Yee Peng Phoon, Caini Liu, Stefanie Avril, Brian Gastman, Timothy Chan, Li Lily Wang
Förderung
- NCI NIH HHS
- Wellcome Trust
- NIH HHS
Zitieren
APA
Ta, H. M., Roy, D., Zhang, K., Alban, T., Juric, I., Dong, J., Parthasarathy, P. B., Patnaik, S., Delaney, E., Gilmour, C., Zakeri, A., Shukla, N., Rupani, A., Phoon, Y. P., Liu, C., Avril, S., Gastman, B., Chan, T., & Wang, L. L. (2024). LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses. Science Immunology, 9(95). https://doi.org/10.1126/sciimmunol.adi7418
Vancouver
Ta HM, Roy D, Zhang K, Alban T, Juric I, Dong J, et al. LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses. Science Immunology. 2024;9(95). doi:10.1126/sciimmunol.adi7418
BibTeX
@article{Ta2024,
author = {Ta, Hieu Minh and Roy, Dia and Zhang, Keman and Alban, Tyler and Juric, Ivan and Dong, Juan and Parthasarathy, Prerana B and Patnaik, Sachin and Delaney, Elizabeth and Gilmour, Cassandra and Zakeri, Amin and Shukla, Nidhi and Rupani, Amit and Phoon, Yee Peng and Liu, Caini and Avril, Stefanie and Gastman, Brian and Chan, Timothy and Wang, Li Lily},
title = {LRIG1 engages ligand VISTA and impairs tumor-specific CD8 + T cell responses},
journal = {Science Immunology},
year = {2024},
volume = {9},
number = {95},
doi = {10.1126/sciimmunol.adi7418}
}
EUVIMED